Markets:

Overview

News

Currencies

International

Treasuries

Jazz Pharmaceuticals plc - Ordinary Shares (NQ:JAZZ)

237.59 -3.38 (-1.40%)

Streaming Delayed Price Updated: 3:36 PM EDT, Jul 1, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Jazz Pharmaceuticals plc - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9

...

17 18 Next >

JAZZ Q3 Deep Dive: New Drug Launches and Portfolio Expansion Drive Strong Results

November 06, 2025

Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) reported Q3 CY2025 results exceeding the market’s revenue expectations, with sales up 6.7% year on year to $1.13 billion. The company expects the...

Via StockStory

Jazz Pharma (JAZZ) Earnings Call Transcript ↗

November 05, 2025

Jazz Pharma (JAZZ) Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Jazz Pharmaceuticals’s (NASDAQ:JAZZ) Q3: Beats On Revenue

November 05, 2025

Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) reported revenue ahead of Wall Streets expectations in Q3 CY2025, with sales up 6.7% year on year to $1.13 billion. The company expects the full...

Via StockStory

Topics Supply Chain

Earnings Scheduled For November 5, 2025 ↗

November 05, 2025

Via Benzinga

Retail Traders Cheer Jazz Pharma After FDA Clears Rare Drug For Brain Tumor ↗

August 06, 2025

Via Stocktwits

Earnings Scheduled For August 5, 2025 ↗

August 05, 2025

Via Benzinga

Insights into Jazz Pharmaceuticals's Upcoming Earnings ↗

November 04, 2025

Via Benzinga

Earnings To Watch: Jazz Pharmaceuticals (JAZZ) Reports Q3 Results Tomorrow

November 03, 2025

Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) will be reporting earnings this Wednesday afternoon. Here’s what to expect.

Via StockStory

Topics Artificial Intelligence

1 Unprofitable Stock with Promising Prospects and 2 Facing Headwinds

October 31, 2025

Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around. Without a clear path to profitability, these businesses risk running out of capital...

Via StockStory

Topics Artificial Intelligence

3 Reasons to Sell JAZZ and 1 Stock to Buy Instead

October 24, 2025

Jazz Pharmaceuticals trades at $138.50 and has moved in lockstep with the market. Its shares have returned 27.1% over the last six months while the S&P 500 has gained 22.9%.

Via StockStory

Topics Government Stocks World Trade

Alkermes Strikes $2.1 Billion Avadel Deal, Gains Access To Narcolepsy Drug Lumryz ↗

October 22, 2025

Alkermes agrees to acquire Avadel for $2.1 billion, adding the successful Lumryz drug and accelerating entry into sleep medicine. Jazz litigation settled.

Via Benzinga

Avadel Pharmaceuticals Soars as Alkermes Announces $2.1 Billion Acquisition

October 22, 2025

DUBLIN, IRELAND – October 22, 2025 – Avadel Pharmaceuticals (NASDAQ: AVDL) shareholders are celebrating today as Alkermes plc (NASDAQ: ALKS) announced a definitive agreement to acquire the company for...

Via MarketMinute

Topics Intellectual Property

Deep Dive Into Jazz Pharmaceuticals Stock: Analyst Perspectives (9 Ratings) ↗

October 20, 2025

Via Benzinga

3 Small Cap Stocks To Play As The Bantamweights Break Out On Wall Street ↗

October 17, 2025

Via Benzinga

3 Cash-Producing Stocks We Approach with Caution

October 17, 2025

While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak...

Via StockStory

SciSparc Expands Biotech Ambitions, Buys Stake In Miza III Ventures ↗

October 15, 2025

SciSparc traded higher after the company announced it had signed a definitive agreement to acquire a controlling stake in Miza III Ventures.

Via Benzinga

SciSparc And AutoMax Call Off Merger ↗

October 06, 2025

SciSparc ends merger with AutoMax, sets loan repayment terms, and refocuses on CNS drug development and innovation.

Via Benzinga

FDA Greenlights Jazz and Roche's Zepzelca-Tecentriq for ES-SCLC Maintenance, Reshaping Lung Cancer Treatment Landscape

October 03, 2025

In a pivotal moment for oncology, the U.S. Food and Drug Administration (FDA) on October 2, 2025, granted approval for the innovative combination of Jazz Pharmaceuticals' (NASDAQ: JAZZ) Zepzelca...

Via MarketMinute

Deep Dive Into Jazz Pharmaceuticals Stock: Analyst Perspectives (9 Ratings) ↗

September 24, 2025

Via Benzinga

Beyond The Numbers: 5 Analysts Discuss Jazz Pharmaceuticals Stock ↗

August 20, 2025

Via Benzinga

Q2 Rundown: Jazz Pharmaceuticals (NASDAQ:JAZZ) Vs Other Pharmaceuticals Stocks

August 17, 2025

As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the pharmaceuticals industry, including Jazz Pharmaceuticals (NASDAQ:JAZZ) and its...

Via StockStory

Topics Artificial Intelligence Intellectual Property

JAZZ Q2 Deep Dive: Pipeline Milestones and Oncology Headwinds Shape Outlook

August 12, 2025

Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) met Wall Street’s revenue expectations in Q2 CY2025, with sales up 2.1% year on year to $1.05 billion. The company’s outlook for the full year was...

Via StockStory

Why Jazz Pharmaceuticals (JAZZ) Stock Is Trading Up Today

August 07, 2025

Shares of biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) jumped 4.8% in the afternoon session after the company received accelerated approval from the U.S. Food and Drug Administration (FDA) for...

Via StockStory

Topics Artificial Intelligence

Jazz (JAZZ) Q2 Revenue Rises 2% ↗

August 06, 2025

Via The Motley Fool

Topics Intellectual Property

JAZZ PHARMACEUTICALS PLC (NASDAQ:JAZZ) Recognized as a Decent Value Stock with Strong Fundamentals ↗

August 06, 2025

Jazz Pharmaceuticals (JAZZ) is a value stock with strong fundamentals, trading below industry averages in P/E and EV/EBITDA, while maintaining high profitability and steady growth potential.

Via Chartmill

Jazz Pharmaceuticals (NASDAQ:JAZZ) Reports Q2 In Line With Expectations But Stock Drops

August 05, 2025

Via StockStory

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Reports Q2 2025 Earnings Miss and Leadership Transition ↗

August 05, 2025

Jazz Pharmaceuticals Q2 2025 results miss revenue and EPS estimates, shares drop 6%. New CEO Renee Gala takes helm amid Xywav growth but investor concerns linger.

Via Chartmill

Topics Earnings

Jazz Pharmaceuticals (JAZZ) To Report Earnings Tomorrow: Here Is What To Expect

August 03, 2025

Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) will be reporting earnings this Tuesday after the bell. Here’s what investors should know.

Via StockStory

Topics Artificial Intelligence

2 Top Stocks I Wouldn't Hesitate to Invest $1,000 in Right Now ↗

July 24, 2025

Via The Motley Fool

Where Jazz Pharmaceuticals Stands With Analysts ↗

July 22, 2025

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

17 18 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.